Compare NCSM & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | ADVB |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.9M | 109.2M |
| IPO Year | 2017 | N/A |
| Metric | NCSM | ADVB |
|---|---|---|
| Price | $54.55 | $4.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 207.5K |
| Earning Date | 06-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 239.22 | N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $142,471,000.00 | N/A |
| Revenue This Year | $11.25 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | $5.58 | ★ $1.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.20 | $0.19 |
| 52 Week High | $53.69 | $5.82 |
| Indicator | NCSM | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 83.10 | 84.08 |
| Support Level | $35.60 | $0.41 |
| Resistance Level | N/A | $5.69 |
| Average True Range (ATR) | 2.22 | 0.66 |
| MACD | 1.39 | 0.16 |
| Stochastic Oscillator | 79.62 | 84.56 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.